So releasing an incomplete or untested product should be the privilege of the innovators, and their customers should be the ones shouldering all expense and risk? Should we apply the same principle to the pharmaceutical industry?
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
replies: